Clinical Trials Sponsored by Shire Development LLC

Total 1360 results

Clinical Study Centers, LLC
Shire

Completed

Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)

Sleep | Attention Deficit Hyperactivity Disorder

United States
Spire, Inc.
Clinimark, LLC

Completed

Spire Medical Health Tag Respiratory Rate Validation in Adults

Respiratory Rate

United States
Takeda
Shire; Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP)

China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
Shire
Takeda Development Center Americas, Inc.

No longer available

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Angioedema | Hereditary Angioedema (HAE)

United States, Canada, Germany, Hungary, Spain
Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy

Metachromatic Leukodystrophy (MLD)

Denmark, Germany, Japan, Australia, France, Brazil, Czechia
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Angioedema

United States, France, Netherlands, Spain, Hungary, Italy, Canada, Poland, Japan, Germany
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

Cytomegalovirus (CMV)

United States, China, Spain, Belgium, Australia, Germany, Italy, Canada, France, Croatia, Singapore, United Kingdom, New Zealand, Korea, Republic of, Russian Federation, Poland, Austria, Greece, Switzerland, Czechia, Hungary, Israel, Turk...
Shire
Takeda Development Center Americas, Inc.

Terminated

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

Eosinophilic Esophagitis (EoE)

United States
Shire
Takeda Development Center Americas, Inc.

Withdrawn

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

COVID-19 Pneumonia
Johnson & Johnson Pharmaceutical Research & Development...
Shire

Completed

Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease

Dementia | Alzheimer's Disease
Shire
Takeda Development Center Americas, Inc.

Recruiting

A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA (NATPARA KAB)

Hypoparathyroidism

United States
Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II (ENABLE)

Hereditary Angioedema (HAE)

Germany, Switzerland, Spain, Israel, Italy, Austria, Portugal, Kuwait
Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy (EMBOLDEN)

Metachromatic Leukodystrophy (MLD)

United States, Canada, Belgium, Israel, Netherlands, United Kingdom, Germany, Spain, Japan, Brazil, Argentina, France, Greece, Italy
Shire
Takeda Development Center Americas, Inc.

Completed

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (SOAR-HI)

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

United States, Spain, Canada, United Kingdom, France, Germany, Italy
Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, United States, United Kingdom, Belgium, Germany, Netherlands, Portugal, Austria, Sweden
Shire
Takeda Development Center Americas, Inc.

Recruiting

Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Hereditary Angioedema (HAE)

France, Austria, Australia, Spain, Czechia, Italy, United Kingdom, Germany, Israel, Ireland, Brazil, Denmark, Greece, Sweden
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease (RAISE)

Sickle Cell Disease

United States
Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

Registry for Participants With Short Bowel Syndrome

Short Bowel Syndrome

United States
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America (EMPOWER)

Hereditary Angioedema (HAE)

Canada, United States, Puerto Rico
Shire
Takeda Development Center Americas, Inc.

Completed

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

Healthy Volunteers

United States
Shire
Takeda Development Center Americas, Inc.

Completed

Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting

Nervous System Diseases

Japan
SCRI Development Innovations, LLC
Janssen Research & Development, LLC

Recruiting

Outpatient Administration of Teclistamab for Multiple Myeloma

Multiple Myeloma

United States
CMP Development, LLC

Not yet recruiting

A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients

Edema Due to Heart Failure or Cirrhosis

India
AMO Development, LLC

Recruiting

Wavefront-guided LASIK for Monovision Treatment of Myopic Subjects With Presbyopia

Refractive Error

United States
CMP Development, LLC

Completed

Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)

Drug Drug Interaction

India
LipimetiX Development, LLC

Completed

Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

Hypercholesterolemia | Hyperlipoproteinemia Type II

Australia
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States, France, Poland, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Israel, Turkey, Ukraine, Japan, Canada, Greece, Korea, Republic of, Netherlands, Brazil, Russian Federation, Puerto Rico, Australia, I... and more
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

Leukemia, Lymphocytic, Chronic, B-Cell

Canada, Belgium, Netherlands, Spain, Israel, United States, Czechia, Denmark, United Kingdom, France, Russian Federation, Turkey, Poland, Sweden
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (Captivate)

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Italy, New Zealand, Poland, Spain
Pharmacyclics LLC.
Janssen Research & Development, LLC

Active, not recruiting

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

United States, Spain, Korea, Republic of, Australia, Austria, Canada, France, Germany, Israel, Italy, Netherlands, Russian Federation, United Kingdom
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia

United States, Spain, France, Canada, Germany, Italy, Australia, United Kingdom, Greece
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, China, Belgium, Germany, Spain, Israel, Turkey, Ukraine, Japan, Taiwan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, Brazil, Russian Federation, Argentina, Norway, Swed... and more
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, France, Poland, Belgium, Germany, Spain, Argentina, Colombia, Israel, Portugal, Russian Federation, Turkey, Ukraine, Canada, Greece, Sweden, Korea, Republic of, United Kingdom, Brazil, Mexico, Czechia
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE™)

Relapsed or Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Austria, Belgium, France, Ireland, Italy, Poland, Spain, United Kingdom
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, Taiwan, Malaysia, Australia
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Mantle Cell Lymphoma

France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Colombia, Portugal, Ukraine, Canada, Netherlands, Sweden, Korea, Republic of, Chile, Brazil, Russian Federation, Hungary, Ireland, Mexico, Czechia
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, Spain, Belgium, Germany, Russian Federation
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Mantle Cell Lymphoma

United States, France, United Kingdom, Belgium, Spain, Israel, Puerto Rico, Poland, Russian Federation
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765

Healthy Volunteers

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (SELENE)

Lymphoma

United States, France, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Belgium, Israel, Russian Federation, Turkey, Japan, Australia, Sweden, Korea, Republic of, Brazil, Puerto Rico, Poland
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)

Chronic Graft Versus Host Disease

United States, Australia, Austria, Canada, China, Croatia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Singapore, Spain, Taiwan
Janssen Research & Development, LLC
Pharmacyclics LLC.

Terminated

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

United States, France, Poland, United Kingdom, Germany, Taiwan, Spain, Bulgaria, Romania, Turkey, Ukraine, Canada, Korea, Republic of, Netherlands, Russian Federation, Belgium, Brazil, Hungary, Czechia, Sweden
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Follicular Lymphoma | B Cell Lymphoma | Non-Hodgkin's Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Diffuse Well-differentiated Lymphocytic Lymphoma | B-Cell Diffuse Lymphoma

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Chronic Lymphocytic Leukemia With 17p Deletion | Small Lymphocytic Lymphoma With 17p Deletion

United States, United Kingdom, Belgium, Germany, Turkey, Australia, Canada, New Zealand, Sweden
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants

Healthy Volunteer

Belgium
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

Healthy Volunteer

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Recruiting

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

Leukemia, Lymphocytic, Chronic, B-Cell | Small Lymphocytic Lymphoma

United States, Spain

Clinical Trials Sponsored by Shire Development LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations